Tolerability of Once-Weekly Alendronate in Patients With Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Study
Authors:
- Ellen Field-MunvesEFEllen Field-Munves
- Richard ToninoRTRichard Tonino
- Mary SmithMSMary Smith
- Richard PetruschkeRPRichard Petruschke
- Lixia WangLWLixia Wang
- John YatesJYJohn Yates
- Anne E. de PappAPAnne E. de Papp
- Joanne PalmisanoJPJoanne Palmisano
- 1 October 2002
- journal article
- clinical trial
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 77 (10) , 1044-1052
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Comparative Safety of Bone Remodeling Agents with a Focus on Osteoporosis TherapiesThe Journal of Clinical Pharmacology, 2001
- Treatment of Osteoporosis with BisphosphonatesRheumatic Disease Clinics of North America, 2001
- Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention TrialThe Journal of Clinical Endocrinology & Metabolism, 2000
- Weekly administration of alendronate: Rationale and plan for clinical assessmentClinical Therapeutics, 2000
- Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT StudyOsteoporosis International, 1999
- Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral FracturesResults From the Fracture Intervention TrialJAMA, 1998
- Alendronate for the Prevention and Treatment of Glucocorticoid-Induced OsteoporosisNew England Journal of Medicine, 1998
- Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fracturesThe Lancet, 1996
- Adverse Effects of BisphosphonatesDrug Safety, 1996
- Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal OsteoporosisNew England Journal of Medicine, 1995